Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 906, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2021.174233
Keywords
DHODH inhibitor; Leflunomide; Teriflunomide; SARS-CoV-2; COVID-19; Drug repurposing
Categories
Ask authors/readers for more resources
DHODH inhibitors have shown promise as antiviral agents against various viruses, including SARS-CoV-2. Studies have shown favorable binding of leflunomide to MPro and spike: ACE2 interface, as well as its involvement in COVID-19 related pathways. Clinical studies have demonstrated the benefits of leflunomide in reducing viral shedding duration, hospital stay duration, and infection severity.
Dihydroorotate dehydrogenase (DHODH) is rate-limiting enzyme in biosynthesis of pyrimidone which catalyzes the oxidation of dihydro-orotate to orotate. Orotate is utilized in the biosynthesis of uridine-monophosphate. DHODH inhibitors have shown promise as antiviral agent against Cytomegalovirus, Ebola, Influenza, Epstein Barr and Picornavirus. Anti-SARS-CoV-2 action of DHODH inhibitors are also coming up. In this review, we have reviewed the safety and efficacy of approved DHODH inhibitors (leflunomide and teriflunomide) against COVID19. In target-centered in silico studies, leflunomide showed favorable binding to active site of MPro and spike: ACE2 interface. In artificial-intelligence/machine-learning based studies, leflunomide was among the top 50 ligands targeting spike: ACE2 interaction. Leflunomide is also found to interact with differentially regulated pathways [identified by KEGG (Kyoto Encyclopedia of Genes and Genomes) and reactome pathway analysis of host transcriptome data] in cogena based drug-repurposing studies. Based on GSEA (gene set enrichment analysis), leflunomide was found to target pathways enriched in COVID-19. In vitro, both leflunomide (EC50 41.49 +/- 8.8 mu mol/L) and teriflunomide (EC50 26 mu mol/L) showed SARS-CoV-2 inhibition. In clinical studies, leflunomide showed significant benefit in terms of decreasing the duration of viral shredding, duration of hospital stay and severity of infection. However, no advantage was seen while combining leflunomide and IFN alpha-2a among patients with prolonged post symptomatic viral shredding. Common adverse effects of leflunomide were hyperlipidemia, leucopenia, neutropenia and liver-function alteration. Leflunomide/teriflunomide may serve as an agent of importance to achieve faster virological clearance in COVID-19, however, findings needs to be validated in bigger sized placebo controlled studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available